Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)

NCT05153330 is registered in ClinicalTrials.gov with Biomea Fusion Inc. as lead sponsor.

NCT NCT05153330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05153330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)
Lead sponsor
Biomea Fusion Inc.
Phase
Phase 1
Overall status
Terminated
Start date
January 24, 2022
Completion date
May 2, 2025
Enrollment
55 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute mixed-phenotype leukemia, acute myeloid leukemia, cancer, chronic lymphocytic leukemia, diffuse large b cell lymphoma, lymphoma, lymphoma, non-hodgkin, multiple myeloma, myeloma, plasma-cell, myelomatosis, plasma cell myeloma, progression, refractory, small lymphocytic lymphoma